Atlantic Medicinal Partners (AMP), a cannabis firm operating in Massachusetts, has ceased operations across its three locations, including its Fitchburg dispensary and cultivation facility. This closure, reported by Worcester Business Journal, occurs as the company faces two lawsuits seeking a combined US$6.11 million in damages related to alleged unpaid debts and loan obligations. The company produced both recreational and medical cannabis products.

The abrupt cessation of business activities by the cannabis firm has left some customers unaware, with its online ordering system reportedly still active for its Fitchburg location as of May 15, 2026. Attempts to contact AMP for comment, including via voicemail and other listed numbers, were unsuccessful.

Atlantic Medicinal Partners’ Operations and Financial Challenges

Founded by CEO Steve Perkins, Chief Operating Officer Jeff Perkins, and business partner Frank Cieri, Atlantic Medicinal Partners first opened its Fitchburg facility in September 2020 at 774 Crawford St. This site, a former LEGO manufacturing facility, served as both a cultivation and dispensary location. The company subsequently expanded its retail footprint with additional dispensaries in Salem and Brockton.

According to information provided to the Worcester Business Journal Research Department, AMP was the 11th-largest cannabis company in Central Massachusetts as of the second quarter of 2025, employing 50 individuals at that time. The company’s closure underscores the financial pressures experienced by some operators in the regulated cannabis market.

Legal Actions Against Atlantic Medicinal Partners

The closure of AMP coincides with two distinct legal challenges alleging significant financial defaults.

Worcester Superior Court Lawsuit

On May 1, 2026, Paul Muzyka, a trustee of the trust owning AMP’s Fitchburg site, filed a lawsuit against the firm in Worcester Superior Court. The lawsuit alleges that AMP failed to pay rent and utilities, accumulating US$112,000 in unpaid rent and US$64,800 in unpaid water and sewer payments to the City of Fitchburg. The filing claims AMP leadership misrepresented the company’s financial stability, stating difficulties were temporary and a path forward existed.

The lawsuit asserts claims of breach of contract, unjust enrichment, negligent and intentional misrepresentation, fraud, and economic waste, seeking US$3.54 million in damages. A judge has approved a preliminary injunction, mandating AMP post a US$300,000 bond for overdue Fitchburg taxes and water bills. Furthermore, a US$1-million attachment was approved on AMP’s non-cannabis assets, with the court finding a reasonable likelihood of AMP’s insolvency.

Middlesex Superior Court Lawsuit

On May 6, 2026, five days after the Worcester filing, Victoria Waters initiated a lawsuit against AMP in Middlesex Superior Court. Ms. Waters, a Walpole resident, stated she provided AMP with a US$1-million loan in 2019. Court documents indicate this five-year loan carried a 15% annual compounding interest rate. The lawsuit alleges AMP failed to repay both the principal and accrued interest by the loan’s March 2024 maturity date.

Ms. Waters’ lawsuit seeks court confirmation of a US$2.57 million award, which was granted in April 2026 through an arbitration process. Joshua Grossman of Boston-based law firm Davis, Malm and D’Agostine is representing Ms. Waters in this ongoing litigation.

Broader Industry Implications

The cannabis firm closure of Atlantic Medicinal Partners is not an isolated incident within the Central Massachusetts cannabis sector. Several other cannabis firms in the region, including those in Clinton and Fitchburg, have either ceased operations or entered receivership due to financial difficulties. Data from a Cannabis Control Commission meeting agenda packet indicates that 31 cannabis licenses were under receivership as of April 16, 2026, reflecting broader economic pressures and operational challenges within the industry.

---

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.